PTPRC and Hyperglycemia: In addition, EX-4 treatment reduced the COX2 (F(1,23) = 31.9798, p<0.001; Fig. 4C), NF-κB (F(1,23) = 8.5548, p<0.01; Fig. 4D), and CD45 (F(1,23) = 6.6012, p<0.05; Fig. 4E) levels against hyperglycemia, and COX1 (F(1,23) = 19.7972, p<0.001; Fig. 4B) and NF-κB (F(1,23) = 8.0, p<0.05; Fig. 4D) against intrahippocampal LPS injection.